Drug Trial News

RSS

Bayer announces data from riociguat Phase III pulmonary arterial hypertension trial

Bayer HealthCare today announced data from the Phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid.

22 Oct 2012

Drospirenone-containing birth control pills associated with increased risk of blood clots

A U.S. Food and Drug Administration-funded study led by the Kaiser Permanente Northern California Division of Research found an increased risk of arterial thrombotic events (ATE) and venous thromboembolic events (VTE) - commonly referred to as blockage of arteries and blood clots, respectively - associated with drospirenone-containing birth control pills compared to four low-dose estrogen combined hormonal contraceptives.

20 Oct 2012

ACT TIL therapy effective in treating metastatic melanoma

Researchers at Moffitt Cancer Center have carried out a clinical trial in which patients with metastatic melanoma were given chemotherapy and an immunotherapy of adoptive cell transfer (ACT) with tumor infiltrating lymphocytes (TIL).

19 Oct 2012

Linezolid proves effective in treating drug-resistant TB

When tested in patients hospitalized with extensively drug-resistant tuberculosis (XDR-TB) unresponsive to previous treatment, linezolid, an antibiotic used to treat severe bacterial infections, proved largely effective when added to the patients' ongoing TB treatment regimen.

19 Oct 2012

Neuralstem initiates second cohort NSI-189 Phase Ib trial in major depressive disorder

Neuralstem, Inc. announced that it has begun dosing the second cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

19 Oct 2012

Long-term multivitamin use associated with prevention of cancer in middle-aged and older men

In a randomized trial that included nearly 15,000 male physicians, long-term daily multivitamin use resulted in a modest but statistically significant reduction in cancer after more than a decade of treatment and follow-up, according to a study appearing in JAMA.

19 Oct 2012

Ustekinumab shows positive results in decreasing debilitating effects of Crohn's Disease

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn's Disease, according to researchers at the University of California San Diego, School of Medicine.

18 Oct 2012

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Pfizer Inc. announced today that a Phase 3 study of INLYTA (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival, versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma.

18 Oct 2012

Trial results of first new TB vaccine candidate in 90 years expected next year

"Researchers will find out early next year whether the first new vaccine against tuberculosis [TB] for 90 years protects against a disease that was once neglected but is now resurgent worldwide," Financial Times reports.

18 Oct 2012

Bayer’s riociguat Phase III trial data on pulmonary hypertension to be presented at ACCP meeting

Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a scientific forum at the American College of Chest Physicians (ACCP) annual meeting October 20 – 25, in Atlanta, GA.

17 Oct 2012

Chloride-restrictive intravenous strategy may decrease incidence of AKI among critically ill patients

In a pilot study assessing the effect of different levels of chloride in intravenous fluids administered to critically ill patients in an intensive care unit, restricting the amount of chloride administration was associated with a significant decrease in the incidence of acute kidney injury and the use of renal replacement therapy, according to a study in the October 17 issue of JAMA.

17 Oct 2012

Resverlogix commences RVX-208 Phase 2 trial in pre-diabetes mellitus

Resverlogix Corp. today announced that it has initiated an exploratory Phase 2 clinical trial in patients with pre-diabetes mellitus to examine the effects of RVX-208 and ApoA-I production on glucose metabolism.

17 Oct 2012

NIAID-funded study to evaluate PPSV23 and PCV13 in Phase Iib pneumococcal trial

Researchers plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier generation vaccine against pneumonia and other pneumococcal diseases.

16 Oct 2012

Saint Louis University to participate in PPV23 vaccine trial for pneumonia

Saint Louis University is participating in a multi-site, National Institutes of Health-sponsored clinical trial in older adults of a new vaccine designed to protect against one of the most common types of pneumonia and related diseases such as bloodstream infections and meningitis.

16 Oct 2012

Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today that the Company will make its first public presentation at the Sixth Annual Parkinson's Disease Therapeutics Conference, sponsored by The Michael J. Fox Foundation for Parkinson's Research, to be held on October 24th in New York City.

15 Oct 2012

Enrollment complete in Idera's IMO-3100 Phase 2 trial for psoriasis

Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.

15 Oct 2012

FIGHT HLH Consortium receives EUR 6 million FP7 grant for testing NovImmune's NI-0501

NovImmune SA announced that the European Commission has awarded a 6 million Euros FP7 grant to the "FIGHT HLH" consortium of institutions to support clinical testing of NovImmune's anti-interferon gamma drug candidate, NI-0501.

15 Oct 2012

Data from Genkyotex’s GKT137831 Phase I studies to be presented at Kidney Week 2012

Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that data from single and multiple dose Phase I studies with the NOX 1 and 4 inhibitor, GKT137831, will be presented at Kidney Week 2012.

15 Oct 2012

No link between folic acid, vitamin B6 and 12 and increased risk of colorectal adenoma

Combined folic acid, vitamin B6 and vitamin B12 supplements had no statistically significant effect on the risk of colorectal adenoma among women who were at high risk for cardiovascular disease, according to a study published October 12 in the Journal of the National Cancer Institute.

15 Oct 2012

GlaxoSmithKline to make clinical trial data available to other researchers

GlaxoSmithKline (GSK) CEO Andrew Witty "said on Thursday detailed data from its clinical trials would be made available to other researchers," Reuters reports, adding, "That would include anonymized patient-level results that sit behind clinical trials of approved and failed drugs."

15 Oct 2012

Drug Trial News

Bayer announces data from riociguat Phase III pulmonary arterial hypertension trial

Drospirenone-containing birth control pills associated with increased risk of blood clots

ACT TIL therapy effective in treating metastatic melanoma

Linezolid proves effective in treating drug-resistant TB

Neuralstem initiates second cohort NSI-189 Phase Ib trial in major depressive disorder

Long-term multivitamin use associated with prevention of cancer in middle-aged and older men

Ustekinumab shows positive results in decreasing debilitating effects of Crohn's Disease

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Trial results of first new TB vaccine candidate in 90 years expected next year

Bayer’s riociguat Phase III trial data on pulmonary hypertension to be presented at ACCP meeting

Chloride-restrictive intravenous strategy may decrease incidence of AKI among critically ill patients

Resverlogix commences RVX-208 Phase 2 trial in pre-diabetes mellitus

NIAID-funded study to evaluate PPSV23 and PCV13 in Phase Iib pneumococcal trial

Saint Louis University to participate in PPV23 vaccine trial for pneumonia

Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference

Enrollment complete in Idera's IMO-3100 Phase 2 trial for psoriasis

FIGHT HLH Consortium receives EUR 6 million FP7 grant for testing NovImmune's NI-0501

Data from Genkyotex’s GKT137831 Phase I studies to be presented at Kidney Week 2012

No link between folic acid, vitamin B6 and 12 and increased risk of colorectal adenoma

GlaxoSmithKline to make clinical trial data available to other researchers

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News